PF-477736 (R)-2-氨基-2-环己基-N-(2-(1-甲基-1H-吡唑-4-基)-6-氧代-5,6-二氢-1H-[1,2]二氮杂卓并[4,5,6-cd]吲哚-8-基)乙酰胺
CAS 952021-60-2 MFCD16038847
化学结构图
SMILES: Cn1cc(-c2[nH]c3cc(NC(=O)C(N)C4CCCCC4)cc4c(=O)[nH]ncc2c34)cn1
化学属性
| Mol. Weight | 419.48 |
|---|---|
| Mol. Formula | C22H25N7O2 |
别名和识别编码
| Synonym | (2R)-2-Amino-2-cyclohexyl-N-[2-(1-methyl-1H-pyrazol-4-yl)-6-oxo-5,6-dihydro-1H-[1,2]diazepino[4,5,6-cd]indol-8-yl]-acetamide (2R)-2-Amino-2-cyclohexyl-N-[2-(1-methyl-1H-pyrazol-4-yl)-6-oxo-5,6-dihydro-1H-[1,2]diazepino[4,5,6-cd]indol-8-yl]-acetamide PF-00477736 PF 00477736 PF-00477736 PF-477736 PF00477736 PF477736 |
|---|---|
| MDL Number | MFCD16038847 |
| CAS Number | 952021-60-2 |
| Chemical Name | PF-477736 |
| Chemical Name Translation | (R)-2-氨基-2-环己基-N-(2-(1-甲基-1H-吡唑-4-基)-6-氧代-5,6-二氢-1H-[1,2]二氮杂卓并[4,5,6-cd]吲哚-8-基)乙酰胺 |
| PubChem Substance ID | 135565545 |
| InChI | InChI=1S/C22H25N7O2/c1-29-11-13(9-25-29)20-16-10-24-28-21(30)15-7-14(8-17(27-20)18(15)16)26-22(31)19(23)12-5-3-2-4-6-12/h7-12,19,27H,2-6,23H2,1H3,(H,26,31)(H,28,30)/t19-/m1/s1 |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- Approved Therapeutics/Drug Candidates, Bioactive Small Molecules, Cell Biology, Cell Signaling and Neuroscience, Checkpoint Kinase (ChK), Kinase/Phosphatase Biology, P, Pfizer Compounds, Serine/Threonine Kinase Biology, Serine/Threonine Kinase Inhibitors
- {SNA} Approved Therapeutics/Drug Candidates, Bioactive Small Molecule Alphabetical Index, Checkpoint Kinase (ChK), Diversification Ready Pharma-Developed Compounds, Kinase/Phosphatase Biology, P-PH, Pfizer Compounds, Serine/Threonine Kinase Biology, Serine/Threonine Kinase Inhibitors, 生物活性小分子, 细胞信号转导和神经科学, 细胞生物学
相关文献及参考
- Zhang C, et al., PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts. Clin. Cancer Res. 15 , 4630-4640, (2009)
- Blasina A, et al., Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol. Cancer Ther. 7 , 2394-2404, (2008)
- Bucher N, Britten CD., G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br. J. Cancer 98 , 523-528, (2008) 摘要
